APR 0 8 2003 E

PTO/SB/30 (10/2001)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

nder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

# REQUEST

FOR

# CONTINUED EXAMINATION (RCE) TRANSMITTAL

Address to: Commissioner for Patents Box RCE Washington, DC 20231

	-ye a valia Olvid control fromber.	'//
Application Number	09/462,816 RECEIV	BOCA
Filing Date	April 5, 2000	
First Named Inventor	Xiaomao Li APR 1 1 20	03
Art Unit	TECH CENTER 16	hn/290(
Examiner Name	Brian A. Whiteman	00,200
Attorney Docket Number	1038-1003 MIS:jb	ľ

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application
Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June
8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

Submission required under 37 CFR §1.114	
a.   Previously submitted	
<ul> <li>i.   Consider the amendment(s)/reply under 37 CFR §1.116 previously</li> </ul>	filed on October 8, 2002
(Any unentered amendment(s) referred to above will be entered).	
ii. Consider the arguments in the Appeal Brief or Reply B	rief previously filed on
···· U Other	
b. 🗵 Enclosed	
i. ⊠ Amendment/Reply iii. ⊠ Information [	Disclosure Statement (IDS)
	tension of Time Request
2. Miscellaneous	
a. ☐ Suspension of action on the above-identified application is	s requested under 37 CER 81 103(c) for
a period of months (Period of suspension shall not exceed 3	months: Fee under 37 CER\$1.17(i) required)
o. Omer	
3. Fees The RCE fee under 37 CFR §1.17(e) is required by 37 CFR §1.1	14 when the RCE is filed.
a. In the Director is hereby authorized to charge the following	fees, or credit any overpayments, to
Deposit Account No.	
RCE fee required under 37 CFR §1.17(e)  1. □ RCE fee required under 37 CFR §1.17(e)	04/10/2003 YPOLITE1 00000024 09462816
ii. 🗵 Extension of time fee (37 CFR §§1.136 and 1.17)	01 FC:1801 750.00 C
III. 🗵 Other <u>Information Disclosure Statement</u>	
b.  Check in the amount of \$ 2,380.00 enclosed	
<ul> <li>C.         Payment by credit card (Form PTO-2038 enclosed)</li> </ul>	
WARNING: Information on this form may become public.	Credit card information should not
be included on this form. Provide credit card information a	nd authorization on PTO-2038.
SIGNATURE OF APPLICANT, ATTORNEY,	OR AGENT REQUIRED
Name (Print / Type) Michael I. Stewart	Registration No. (Attorney / Agent) 24,973
Signature Michael 1. STEWART	Date April 7, 2003
CERTIFICATE OF MAILING OR TR	ANSMISSION
I hereby certify that this correspondence is being deposited with the United States P	netal Service with sufficient postogo on first along will
an envelope addressed to: Commissioner For Patents, Box RCE, Washington, DC andTrademark	20231, or facsimile transmitted to the U.S. Patent
Name (Print / Type) Janet Bist	
Signature J. Rist	Date   April 7, 2003
Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary d	enending upon the people of the individual area. A

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Assistant Commissioner for Patents, Box RCE, Washington, DC 20231.



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

X. Li, et al.

Appl'n. No.

09/462,816

Filed

April 5, 2000

Title

#20/K.T. 4/15 NUCLEIC ACID VACCINE ENCODING G PROTEIN

OF RESPIRATORY SYNCYTIAL VIRUS

Grp./A.U.

1635

Examiner

Brian A. Whiteman

Docket No.

1038-1003 MIS:jb

Date

April 7, 2003

### **BY COURIER**

The Commissioner of Patents and Trademarks. **Box Amendment** Washington, D.C. 20231, U.S.A.

#### PRELIMINARY AMENDMENT

Sir:

Please amend the above-identified application as follows: